
Health Dictionary
Reliable, easy-to-read patient information on common medical conditions β written in plain language, free of jargon, and grounded in current evidence. Browse the most frequent diagnoses, understand what they mean for everyday life, and learn which steps and questions help you have a focused conversation with your doctor.
Barrett's esophagus natural history, complications and prognosis
Introduction
Overview
Overview
Common complications of Barrett’s esophagus include esophageal carcinoma, esophageal stricture and esophageal ulcers.
Natural History, Complications, and Prognosis
Natural History, Complications, and Prognosis
Natural History
Barrett’s esophagus is associated with increased risk of esophageal cancer. Follow-up endoscopy is recommended for dysplasia or cancer evaluation.
- The symptoms of Barrett’s esophagus usually develop in the fifth/sixth decade of life, and start with symptoms of GERD such as heartburn, regurgitation and dysphagia.
- If left untreated, 100 to 400 out of 100,000 patients with Barrett’s esophagus may progress to develop esophageal adenocarcinoma. [1][2][3][4][5]
Complications
- Common complications of Barrett’s esophagus include:
Progression
- From low-grade dysplasia to high-grade dysplasia or esophageal adenocarcinoma: 0.5 to 13.4% per year
- From high-grade dysplasia to cancer: 6% per year[8]
Prognosis
Prognosis
- Prognosis is generally good for Barrett’s esophagus, but if it is associated with esophageal adenocarcinoma then 5 year survival rate of patients with Barrett’s esophagus is approximately 20%.[9]
References
References
- β Drewitz DJ, Sampliner RE, Garewal HS (1997). “The incidence of adenocarcinoma in Barrett’s esophagus: a prospective study of 170 patients followed 4.8 years”. Am J Gastroenterol. 92 (2): 212β5. PMIDΒ 9040193.
- β Eckardt VF, Kanzler G, Bernhard G (2001). “Life expectancy and cancer risk in patients with Barrett’s esophagus: a prospective controlled investigation”. Am J Med. 111 (1): 33β7. PMIDΒ 11448658.
- β Rastogi A, Puli S, El-Serag HB, Bansal A, Wani S, Sharma P (2008). “Incidence of esophageal adenocarcinoma in patients with Barrett’s esophagus and high-grade dysplasia: a meta-analysis”. Gastrointest Endosc. 67 (3): 394β8. doi:10.1016/j.gie.2007.07.019. PMIDΒ 18045592.
- β Sharma P, Falk GW, Weston AP, Reker D, Johnston M, Sampliner RE (2006). “Dysplasia and cancer in a large multicenter cohort of patients with Barrett’s esophagus”. Clin Gastroenterol Hepatol. 4 (5): 566β72. doi:10.1016/j.cgh.2006.03.001. PMIDΒ 16630761.
- β Desai TK, Krishnan K, Samala N, Singh J, Cluley J, Perla S; et al. (2012). “The incidence of oesophageal adenocarcinoma in non-dysplastic Barrett’s oesophagus: a meta-analysis”. Gut. 61 (7): 970β6. doi:10.1136/gutjnl-2011-300730. PMIDΒ 21997553.
- β Hvid-Jensen F, Pedersen L, Drewes AM, SΓΈrensen HT, Funch-Jensen P (2011). “Incidence of adenocarcinoma among patients with Barrett’s esophagus”. N Engl J Med. 365 (15): 1375β83. doi:10.1056/NEJMoa1103042. PMIDΒ 21995385.
- β 7.0 7.1 Milind R, Attwood SE (2012). “Natural history of Barrett’s esophagus”. World J Gastroenterol. 18 (27): 3483β91. doi:10.3748/wjg.v18.i27.3483. PMCΒ 3400849. PMIDΒ 22826612.
- β Spechler SJ, Sharma P, Souza RF, Inadomi JM, Shaheen NJ (2011). “American Gastroenterological Association medical position statement on the management of Barrett’s esophagus”. Gastroenterology. 140 (3): 1084β91. doi:10.1053/j.gastro.2011.01.030. PMIDΒ 21376940. Unknown parameter
|month=ignored (help) - β Howlader N, Noone AM, Krapcho M, Garshell J, Miller D, Altekruse SF, Kosary CL, Yu M, Ruhl J, Tatalovich Z,Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin KA (eds). SEER Cancer Statistics Review, 1975-2011, National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/1975_2011/, based on November 2013 SEER data submission, posted to the SEER web site, April 2014.
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Amresh Kumar MD [2]
